Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Pancreatic Cancer
NCT03138720Phase 2Completed
- Sponsor
- HonorHealth Research Institute
- Start
- May 2017
- Primary completion
- Jul 2023
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of nab-paclitaxel, gemcitabine, cisplatin and paricalcitol in pancreatic adenocarcinoma (PDAC) (2 cohorts), sponsored by HonorHealth Research Institute. Primary endpoint: CA 19-9 Normalization at 26 weeks. Started May 2017; status: completed.
02
Drugs
nab-paclitaxelgemcitabinecisplatinparicalcitol
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03138720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138720.